Neubond specialises in personalised home rehabilitation devices for stroke patients to address their mobility constraints. Its devices establish a direct connection to the patient’s body, integrating therapy into daily life. The company is developing an at-home stroke rehabilitation wristband that reads faint electrical signals from muscles and shows patients in real time when their attempt to move has activated a muscle.
Investment Rounds
Capital activity and funding progression
Industries
Frequently Asked Questions
Where is Neubond located?
Neubond is located in London, United Kingdom.
What industries does Neubond operate in?
Neubond operates in the following industries: Medical Equipment Manufacturing.
When was Neubond founded?
Neubond was founded on 2026-06-24.
How much total funding has Neubond raised?
Neubond has raised a total of $1,500,000.
Who are the investors in Neubond?
The investors in Neubond are: WASEDA University Ventures (WUV), SFC Capital, New Wave Ventures LLP.
What is the primary purpose of the Neubond device?
Neubond has developed a wearable, autonomous device designed to assist stroke survivors with neuro-rehabilitation by reinforcing the connection between their intention to move and actual muscle activation.
How does the Neubond technology work?
The device uses sensors in a wearable bracelet to detect electrical signals from a patient's muscles when they attempt to move. It then provides real-time sensory feedback through electrical stimulation, which helps the brain rebuild neural pathways, a process known as neuroplasticity.
Can I purchase the Neubond device for personal use?
The technology is currently in development and undergoing clinical trials; it is not yet commercially available for direct purchase.
How can I get involved or participate in Neubond trials?
Interested individuals can join the waiting list for early access to pilot and beta testing programs by visiting the official website or by contacting the team directly through their email.
Who founded Neubond?
Neubond was co-founded by Dr. Patrick Sagastegui and Jumpei Kashiwakura, who met while working on a prosthetic hand project at Imperial College London.